CTXR vs. VTGN, DARE, PTI, MACK, KALV, PEPG, TVTX, APLT, ANNX, and ERAS
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Vistagen Therapeutics (VTGN), Daré Bioscience (DARE), Proteostasis Therapeutics (PTI), Merrimack Pharmaceuticals (MACK), KalVista Pharmaceuticals (KALV), PepGen (PEPG), Travere Therapeutics (TVTX), Applied Therapeutics (APLT), Annexon (ANNX), and Erasca (ERAS). These companies are all part of the "medical" sector.
Vistagen Therapeutics (NASDAQ:VTGN) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.
Vistagen Therapeutics currently has a consensus target price of $19.00, suggesting a potential upside of 392.23%. Citius Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 473.48%. Given Vistagen Therapeutics' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Vistagen Therapeutics.
Citius Pharmaceuticals has a net margin of 0.00% compared to Citius Pharmaceuticals' net margin of -3,073.51%. Vistagen Therapeutics' return on equity of -40.78% beat Citius Pharmaceuticals' return on equity.
Vistagen Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
Vistagen Therapeutics received 74 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 62.16% of users gave Citius Pharmaceuticals an outperform vote.
78.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 1.0% of Vistagen Therapeutics shares are held by company insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Citius Pharmaceuticals has lower revenue, but higher earnings than Vistagen Therapeutics.
In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 5 mentions for Citius Pharmaceuticals and 2 mentions for Vistagen Therapeutics. Citius Pharmaceuticals' average media sentiment score of 0.94 beat Vistagen Therapeutics' score of 0.41 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Summary
Citius Pharmaceuticals beats Vistagen Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
